Skip to main content
Clinical Trials/NCT03450902
NCT03450902
Completed
Phase 2

Combination Therapy With Chinese Herbal Formula, Yiqi Suoquan Granule, and Acupuncture for Female Mixed Urinary Incontinence

Guang'anmen Hospital of China Academy of Chinese Medical Sciences1 site in 1 country136 target enrollmentMarch 14, 2018

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Urinary Incontinence
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Enrollment
136
Locations
1
Primary Endpoint
Change in incontinence episode per 24 h
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to determine whether combination therapy with Chinese herbal formula, Yiqi Suoquan granule, and acupuncture is effective in the treatment of female mixed urinary incontinence.

Detailed Description

This factorial, randomized, controlled trial is aimed to assess the effectiveness of combination therapy with Chinese herbal formula, Yiqi Suoquan granule, and acupuncture in the treatment of female mixed urinary incontinence (MUI). Eligible participants will be randomly allocated to receiving combination therapy with Yiqi Suoquan granule and acupuncture, Yiqi Suoquan ganule plus sham acupuncture, placebo plus acupuncture, or placebo plus sham acupuncture. To minimize the evaluation bias, the outcome assessors and statisticians will be masked to treatment allocation besides participants.

Registry
clinicaltrials.gov
Start Date
March 14, 2018
End Date
April 18, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Factorial
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ran Pang

Associate Professor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • (1) female, leaking with urgency and with physical activity, coughing or sneezing (MUI) for more than 1 year; (2) recorded more than 1 incontinent episode per 24 hours in their bladder diary

Exclusion Criteria

  • (1) with acute urinary tract infection; (2) with bladder outlet obstruction, (3) with neurogenic bladder (4) with interstitial cystitis, (5) with pelvic organ prolapse more than stage 2 (6) previous anti-incontinence surgery or a post-void residual urine volume more than 100 mL.

Outcomes

Primary Outcomes

Change in incontinence episode per 24 h

Time Frame: 8 week (post-treatment) and 12 week (follow-up)

assessed by 72 h bladder diary

Secondary Outcomes

  • proportion of participants with more than 50% improvement in incontinence episodes per 24h(8 week (post-treatment))
  • Change in I-QOL questionnaire(8 week (post-treatment) and 12 week (follow-up))
  • Change in ICIQ-SF questionnaire(8 week (post-treatment) and 12 week (follow-up))

Study Sites (1)

Loading locations...

Similar Trials